Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "MAA"

42 News Found

Ministry of Ayush and Ministry of Women and Child Development join hands for Nutritional Improvement in adolescent girls through Ayurveda interventions
News | February 27, 2024

Ministry of Ayush and Ministry of Women and Child Development join hands for Nutritional Improvement in adolescent girls through Ayurveda interventions

Both the Ministries signed MoU for anaemia control among adolescent girls using Ayurveda interventions


FDA and EMA accept Marstacimab regulatory submissions for the treatment of Hemophilia A and B
Drug Approval | December 13, 2023

FDA and EMA accept Marstacimab regulatory submissions for the treatment of Hemophilia A and B

Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting


Brenntag Specialties and Zeochem expand collaboration for Pharma EMEA
Supply Chain | November 17, 2023

Brenntag Specialties and Zeochem expand collaboration for Pharma EMEA

Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels


Apitoria Pharma  appoints Dr. Sanjay Chaturvedi as CEO
People | April 06, 2023

Apitoria Pharma appoints Dr. Sanjay Chaturvedi as CEO

Venkat Nageswar Chalasani has been appointed as an Independent Director of Apitoria Pharma with effect from April 4, 2023


LogiPharma launches Asian focused summit, coming to Singapore in June 2023
News | April 05, 2023

LogiPharma launches Asian focused summit, coming to Singapore in June 2023

The summit encompasses multiple verticals, spanning from pharmaceuticals, biotech, life sciences, and the Healthcare sector to ensure an unbiased and comprehensive view on the future of the function.


Hutchmed completes rolling submission of NDA to USFDA for fruquintinib
Drug Approval | April 03, 2023

Hutchmed completes rolling submission of NDA to USFDA for fruquintinib

NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China


Pfizer’s Elranatamab receives FDA and EMA filing acceptance
Drug Approval | February 25, 2023

Pfizer’s Elranatamab receives FDA and EMA filing acceptance

Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma


USFDA accepts biologics license application for Pfizer’s respiratory syncytial virus maternal vaccine candidate for priority review
Drug Approval | February 22, 2023

USFDA accepts biologics license application for Pfizer’s respiratory syncytial virus maternal vaccine candidate for priority review

This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency


Dr. Reddy’s completes clinical studies of its rituximab biosimilar for filing in the U.S., Europe
Drug Approval | January 21, 2023

Dr. Reddy’s completes clinical studies of its rituximab biosimilar for filing in the U.S., Europe

Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions


Valneva and Pfizer report antibody persistence data for lyme disease vaccine candidate
News | December 05, 2022

Valneva and Pfizer report antibody persistence data for lyme disease vaccine candidate

Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule